Abiopharma

The first participant, based in Australia, was dosed in a global Phase I trial of IMG-007, an investigational OX40 antagonistic monoclonal antibody. The Phase I study is a double-blind, randomized, placebo-controlled, dose-escalation study in healthy volunteers and adult patients with moderate to severe atopic dermatitis.